BACKGROUND: It has been shown that expression of the potent angiogenic factor, vascular endothelial growth factor (VEGF), and its receptors, flt-1 (VEGFR-1) and KDR/Flk-1 (VEGFR-2), increased during the development of liver fibrosis. AIMS: To elucidate the in vivo role of interaction between VEGF and its receptors in liver fibrogenesis. METHODS: A model of CCl(4) induced hepatic fibrosis was used to assess the role of VEGFR-1 and VEGFR-2 by means of specific neutralising monoclonal antibodies (R-1mAb and R-2mAb, respectively). R-1mAb and R-2mAb were administered after two weeks of treatment with CCl(4), and indices of fibrosis were assessed at eight weeks. RESULTS: Hepatic VEGF mRNA expression significantly increased during the development of liver fibrosis. Both R-1mAb and R-2mAb treatments significantly attenuated the development of fibrosis associated with suppression of neovascularisation in the liver. Hepatic hydroxyproline and serum fibrosis markers were also suppressed. Furthermore, the number of alpha-smooth muscle actin positive cells and alpha1(I)-procollagen mRNA expression were significantly suppressed by R-1mAb and R-2mAb treatment. The inhibitory effect of R-2mAb was more potent than that of R-1mAb, and combination treatment with both mAbs almost completely attenuated fibrosis development. Our in vitro study showed that VEGF treatment significantly stimulated proliferation of both activated hepatic stellate cells (HSC) and sinusoidal endothelial cells (SEC). VEGF also significantly increased alpha1(I)-procollagen mRNA expression in activated HSC. CONCLUSIONS: These results suggest that the interaction of VEGF and its receptor, which reflected the combined effects of both on HSC and SEC, was a prerequisite for liver fibrosis development.
BACKGROUND: It has been shown that expression of the potent angiogenic factor, vascular endothelial growth factor (VEGF), and its receptors, flt-1 (VEGFR-1) and KDR/Flk-1 (VEGFR-2), increased during the development of liver fibrosis. AIMS: To elucidate the in vivo role of interaction between VEGF and its receptors in liver fibrogenesis. METHODS: A model of CCl(4) induced hepatic fibrosis was used to assess the role of VEGFR-1 and VEGFR-2 by means of specific neutralising monoclonal antibodies (R-1mAb and R-2mAb, respectively). R-1mAb and R-2mAb were administered after two weeks of treatment with CCl(4), and indices of fibrosis were assessed at eight weeks. RESULTS: Hepatic VEGF mRNA expression significantly increased during the development of liver fibrosis. Both R-1mAb and R-2mAb treatments significantly attenuated the development of fibrosis associated with suppression of neovascularisation in the liver. Hepatic hydroxyproline and serum fibrosis markers were also suppressed. Furthermore, the number of alpha-smooth muscle actin positive cells and alpha1(I)-procollagen mRNA expression were significantly suppressed by R-1mAb and R-2mAb treatment. The inhibitory effect of R-2mAb was more potent than that of R-1mAb, and combination treatment with both mAbs almost completely attenuated fibrosis development. Our in vitro study showed that VEGF treatment significantly stimulated proliferation of both activated hepatic stellate cells (HSC) and sinusoidal endothelial cells (SEC). VEGF also significantly increased alpha1(I)-procollagen mRNA expression in activated HSC. CONCLUSIONS: These results suggest that the interaction of VEGF and its receptor, which reflected the combined effects of both on HSC and SEC, was a prerequisite for liver fibrosis development.
Authors: C J Bruns; W Liu; D W Davis; R M Shaheen; D J McConkey; M R Wilson; C D Bucana; D J Hicklin; L M Ellis Journal: Cancer Date: 2000-08-01 Impact factor: 6.860
Authors: H Yoshiji; S Kuriyama; Y Miyamoto; U P Thorgeirsson; D E Gomez; M Kawata; J Yoshii; Y Ikenaka; R Noguchi; H Tsujinoue; T Nakatani; S S Thorgeirsson; H Fukui Journal: Hepatology Date: 2000-12 Impact factor: 17.425
Authors: H Yoshiji; S Kuriyama; D J Hicklin; J Huber; J Yoshii; Y Miyamoto; M Kawata; Y Ikenaka; T Nakatani; H Tsujinoue; H Fukui Journal: Hepatology Date: 1999-11 Impact factor: 17.425
Authors: M Prewett; J Huber; Y Li; A Santiago; W O'Connor; K King; J Overholser; A Hooper; B Pytowski; L Witte; P Bohlen; D J Hicklin Journal: Cancer Res Date: 1999-10-15 Impact factor: 12.701
Authors: Volker Schmitz; Esther Raskopf; Maria Angeles Gonzalez-Carmona; Annabelle Vogt; Christian Rabe; Ludger Leifeld; Miroslaw Kornek; Tilman Sauerbruch; Wolfgang H Caselmann Journal: Gut Date: 2006-06-29 Impact factor: 23.059
Authors: Liu Yang; Junghee Kwon; Yury Popov; Gabriella B Gajdos; Tamas Ordog; Rolf A Brekken; Debabrata Mukhopadhyay; Detlef Schuppan; Yan Bi; Douglas Simonetto; Vijay H Shah Journal: Gastroenterology Date: 2014-02-04 Impact factor: 22.682